新FIGO分期对宫颈癌影像学的影响及影像的作用
2018年FIGO宫颈癌分期将肿瘤大小和淋巴结转移纳入分期,影像学作用显著提升。本文综述各影像模态在肿瘤大小测量和淋巴结评估中的诊断能力,并概述MRI基本影像表现及影像在疗效和预后预测中的作用。
要点
- 2018 FIGO分期将肿瘤大小和淋巴结转移纳入分期,影像成为分期关键依据。
- MRI高空间分辨率用于肿瘤大小测量,PET/CT对淋巴结评估准确性高。
- 影像组学和深度学习新技术可用于疗效反应和预后预测。
核心结论
- 2018 FIGO分期纳入肿瘤大小和淋巴结转移,影像学在宫颈癌分期中作用重要。
- MRI适合肿瘤大小测量,PET/CT对淋巴结评估准确性高。
研究设计与样本
- 综述,介绍2018 FIGO分期变化背景及各影像模态诊断能力,未报告检索范围和纳入文献数量。
关键影像表现/征象
- MRI具有高空间分辨率,可用于肿瘤大小测量。
- 不同MRI序列和模态可针对评估重点提供特征性表现,并有助于早期发现复发肿瘤。
临床应用与阅片要点
- 宫颈癌分期应结合MRI测量肿瘤大小和PET/CT评估淋巴结转移。
- 根据评估重点选择MRI序列以准确诊断和早期检测复发。
局限性
- 综述未报告系统检索策略和纳入文献数量,证据汇总方法不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
International Federation of Gynecology and Obstetrics (FIGO) staging, which is the fundamentally important cancer staging system for cervical cancer, has changed in 2018. New FIGO staging includes considerable progress in the incorporation of imaging findings for tumour size measurement and evaluating lymph node (LN) metastasis in addition to tumour extent evaluation. MRI with high spatial resolution is expected for tumour size measurements and the high accuracy of positron emmision tomography/CT for LN evaluation. The purpose of this review is firstly review the diagnostic ability of each imaging modality with the clinical background of those two factors newly added and the current state for LN evaluation. Secondly, we overview the fundamental imaging findings with characteristics of modalities and sequences in MRI for accurate diagnosis depending on the focus to be evaluated and for early detection of recurrent tumour. In addition, the role of images in treatment response and prognosis prediction is given with the development of recent technique of image analysis including radiomics and deep learning.
引用
- Kido A, Nakamoto Y. Implications of the new FIGO staging and the role of imaging in cervical cancer. Br J Radiol. 2021. PMID: 33989030. doi:10.1259/bjr.20201342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。